The emergence of GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro is reshaping obesity treatment, creating a wave of excitement among researchers and patients alike. At a recent obesity conference, Martin Binks, chair of George Mason University’s Department of Nutrition and Food Studies, reflected on the momentous shift: “Can you believe we finally reached this moment, that we lived long enough to see this?”
These medications, originally developed to regulate appetite and blood sugar, have demonstrated dramatic weight-loss effects, prompting widespread media attention and skyrocketing demand. “They’ve changed the game for metabolic systems disrupted by obesity,” Binks said.
Yet medical experts caution that GLP-1s are not a standalone solution. Raedeh Basiri, an assistant professor of nutrition and registered dietitian at George Mason, has observed patients who successfully lose weight on these drugs but experience nutrient deficiencies that affect energy, hormone regulation, and even hair health. Rapid weight loss can also contribute to muscle loss if dietary intake does not adequately support lean tissue.
Both Binks and Basiri emphasize that effective obesity treatment requires a personalized, multidisciplinary approach. They recommend combining medication with nutrition guidance, physical activity, and psychological support whenever possible.
“In a perfect world, these medicines would be dispensed in multidisciplinary clinics, and everybody would get a medical consult, an exercise physiologist consult, and a registered dietitian,” Binks said.
In practice, however, many patients receive only a prescription from a physician without additional support. Basiri noted, “They’re just seeing a physician, getting a prescription, and that’s it.”
Access and cost remain major barriers. Some patients who do not meet medical criteria are able to obtain GLP-1 prescriptions through online services, while those most likely to benefit are sometimes excluded due to high costs and inconsistent insurance coverage. “Access to obesity care is essential for all who live with obesity. For those who are economically disadvantaged, these medicines are largely out of reach,” Binks said, advocating for Medicaid and Medicare coverage of weight-loss prescriptions.
Looking ahead, Binks predicts broader access as GLP-1 medications become available in pill form, a development already on the horizon.
Despite the hype surrounding these drugs, Basiri urges a holistic approach. “Without a team-based strategy that treats the whole person, we’re only solving part of the problem for a small segment of those in need,” she said.
For nutrition professionals, the rise of GLP-1 medications reinforces their essential role in obesity care rather than diminishing it. “The spotlight on these medications only enhances the role of nutrition and dietary recommendations for people with obesity,” Basiri added.
